Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News Analysis
Nature Reviews Drug Discovery 7, 473–474 (1 June 2008) | doi:10.1038/nrd2596
Bendamustine
&
Abstract
In March 2008, bendamustine hydrochloride (Treanda; Cephalon), a DNA alkylating anticancer agent, was approved by the US FDA for the treatment of chronic lymphocytic leukaemia. Chronic lymphocytic leukaemia (CLL), which results from the production of long-lived abnormal lymphocytes, is the most common type of leukaemia in North America and Europe.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
